Rare Renal Disorders
Pharmacotherapies
Explore facts and recommendations for pharmacological treatments for rare renal disorders.
We didn't find any resources that match your selection.
Please adjust your filter(s) and try again.
PHYOX2 infographic
This infographic provides an overview of PHYOX2, the pivotal randomized study of nedosiran in PH1 or PH2
PHYOX3 infographic
This infographic summarizes the safety and efficacy of nedosiran in patients with PH1 based 2.5 year interim analysis of the PHYOX3 trial
Find more information
Find product information
Explore our portfolio of products for treating rare renal disorders, including prescribing information, safety data sheets and storage and stability information.
Continuing education
Explore accredited education opportunities for rare renal disorders, supported by Novo Nordisk and provided by third-party organizations.
The purpose of this site is to provide relevant medical and scientific information about Novo Nordisk products and areas of therapeutic interest. Information about investigational products or investigational uses of approved products neither implies FDA approval for these products or uses, nor establishes the safety or efficacy of these products or uses. There is no guarantee that any investigational product or investigational use will receive FDA approval or become commercially available in the United States. Novo Nordisk does not recommend or suggest use of its products in any manner inconsistent with FDA-approved labeling.
This site is intended for United States healthcare professionals only. The information on this site—including all product information—pertains to residents of the United States only. Any products referenced on this site may have different labelling in different countries.
